Construction of nanostructured DNA harbouring phosphorodiamidate morpholino oligonucleotide for controlled tissue distribution in mice

<p>Phosphorodiamidate morpholino oligonucleotides (PMOs) are a class of antisense oligonucleotides used in the treatment of neuromuscular diseases. Their major drawbacks are high blood clearance and poor cellular delivery. Previously, we demonstrated that tripod-like nanostructured DNA, or tripodna, was efficiently taken up by macrophages and dendritic cells. In this study, we used iodine-125(<sup>125</sup>I)-labelled PMOs, designed a tripodna harbouring an <sup>125</sup>I-PMO (<sup>125</sup>I-PMO/tripodna), and evaluated whether this tripodna could control the pharmacokinetic properties of PMO. Gel electrophoresis showed that <sup>125</sup>I-PMO was almost completely incorporated into the tripodna. Compared to <sup>125</sup>I-PMO, <sup>125</sup>I-PMO/tripodna was more efficiently taken up by macrophage-like RAW264.7 cells. Moreover, after intravenous injection into mice, the area under the plasma concentration–time curve of <sup>125</sup>I-PMO/tripodna was significantly larger than that of <sup>125</sup>I-PMO. The distribution of <sup>125</sup>I-PMO/tripodna in the liver and spleen at 24 h was 32- and 51-fold higher than that of <sup>125</sup>I-PMO, respectively. The fractionation of liver cells revealed that non-parenchymal cells were the major cells contributing to the hepatic uptake of <sup>125</sup>I-PMO/tripodna. These results indicate that tripodna has the potential to deliver PMO, particularly to the liver and spleen.</p>